| |
|
Form Serial Number: |
DA20240715E00029
|
| 1.
Date of relevant event: |
10/07/2024
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
02228 |
| 4.
Name of listed corporation: |
QuantumPharm Inc. - P |
| 5.
Class of shares: |
Ordinary Shares |
| 6.
Number of issued shares in class: |
3,415,568,761 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
Ma |
| (Other names) |
Jian |
|
|
|
| 10.
Name of director (Chinese): |
马健 |
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1711 | Miscellaneous
Other (you must briefly describe the relevant event in the Supplementary Information box) |
|
| 2201 | Interest of corporation controlled by you |
|
| 2201 | Interest of corporation controlled by you |
|
227,241,967 |
|
|
|
|
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 227,241,967 | 6.67 |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 227,241,967 | 6.65 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| |
| 2307 | Founder of a discretionary trust who can influence how the trustee exercises his discretion |
| |
| 2201 | Interest of corporation controlled by you |
| |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| QuantumPharm Employee Holdings Limited | Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola, British Virgin Islands | 马健 | 100.00 | Y | |
| Crete Helix Ltd. | Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola, British Virgin Islands | MH International Limited | 99.00 | Y | |
| MH International Limited | Coastal Building, Wickham’s Cay II, P. O. Box 2221, Road Town, Tortola, British Virgin Islands | 马健 | 100.00 | N | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| MH Fund Trust | Addresses of individuals are not displayed. | | 5103 | Founder of a discretionary trust who can influence how the trustee exercises his discretion |
| |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a director is interested under sections 317 and 318 | |
|
| |
| 34.
Supplementary information: |
方格24：由于行使超额配售权额外发行8,796,000股份，马健持有的股份比例改变。Box 27: 于首次公开发售前员工持股计划中，马健(i)享有45,230,342股份的购股权; 及(ii)作为咨询委员会的唯一成员控制 QuantumPharm Employee Holdings Limited持有的涉及59,103,125股份的购股权。根据马健与Crete Helix Ltd.签订的授权书，QuantumPharm Holdings Limited获授权行使由Crete Helix Ltd. 持有122,908,500股份所附带的投票权。
|
| 35.
Log/Serial Number of the previous form: |
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
|
|
Date of filing this Form 3A: |
15/07/2024
(dd/mm/yyyy)
|
| |